中金三连调该医药股目标价背后:多管线进入临床关键阶段

动脉网
15 May

远大医药多管线进入临床关键阶段,中金三次上调其目标价。其自研药物STC3141脓毒症II期临床成功,TLX591前列腺癌药国际III期临床获受理,并计划今年递交上市申请。同时,公司另一核药GPN02006也将在国际会议上公布研究成果。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10